Fabhalta Kidney Treatment Shows Promise in Slow...

By João L. Carapinha

October 21, 2025

Novartis has announced positive final results from the Phase III APPLAUSE-IgAN trial, which demonstrated that Fabhalta kidney treatment (iptacopan) achieved a statistically significant and clinically meaningful slowing of kidney function decline i...
Tukysa Breast Cancer Therapy Boosts Progression-Free Survival in Advanced Cases
Lurbinectedin SCLC Therapy: FDA Approval and Its Economic Implications
Transforming Healthcare with the Gene Therapy Access Model
PhRMA’s Patient Access Investment: $500 Billion Commitment to Domestic ...
The Market Dynamics of Track One Patent Strategy in Pharmaceuticals
NHS Productivity Gains at Risk: Balancing Innovation and Cost Control
Transforming Cancer Treatment: Implications of Subcutaneous Pembrolizumab App...
Addressing GLP-1 Access Inequity: Lessons from HIV/AIDS Mobilization
NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Su...
CAPVAXIVE Pneumococcal Vaccine Delivers Strong Immune Response in At-Risk Youth
Ending Unproven Fertility Treatments: NICE Calls for Evidence-Based Care in C...
Mounjaro Price Increase UK: Impacts on Access and Health Economics